Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Kala Pharmaceuticals Inc (KALA)

Kala Pharmaceuticals Inc (KALA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2017 Equity Incentive Plan in...

KALA : 4.05 (+1.00%)
Kala Pharmaceuticals Receives FDA Complete Response Letter for KPI-121 0.25% NDA and Plans to Respond with Data From STRIDE 3 Trial

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that it received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Company's new drug application...

KALA : 4.05 (+1.00%)
Kala Pharmaceuticals Becomes Oversold (KALA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

KALA : 4.05 (+1.00%)
Kala Pharmaceuticals (KALA) Reports Q2 Loss, Lags Revenue Estimates

Kala Pharma (KALA) delivered earnings and revenue surprises of 5.41% and -21.43%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

KALA : 4.05 (+1.00%)
Kala Pharmaceuticals Reports Second Quarter 2019 Financial Results

Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY(TM) mucus-penetrating particle...

KALA : 4.05 (+1.00%)
Kala Pharmaceuticals to Report Second Quarter 2019 Financial Results and Host Conference Call

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY(TM) mucus-penetrating particle (MPP)...

KALA : 4.05 (+1.00%)
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2017 Equity Incentive...

KALA : 4.05 (+1.00%)
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2017 Equity Incentive...

KALA : 4.05 (+1.00%)
Kala Pharmaceuticals (KALA) Reports Q1 Loss, Tops Revenue Estimates

Kala Pharma (KALA) delivered earnings and revenue surprises of 17.28% and 43.78%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

KALA : 4.05 (+1.00%)
Kala Pharmaceuticals Reports First Quarter 2019 Financial Results

Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY(TM) mucus-penetrating...

KALA : 4.05 (+1.00%)
Kala Pharmaceuticals to Present at Bank of America Merrill Lynch 2019 Health Care Conference

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY(TM) mucus-penetrating...

KALA : 4.05 (+1.00%)
Kala Pharmaceuticals to Report First Quarter 2019 Financial Results and Host Conference Call

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY(TM) mucus-penetrating...

KALA : 4.05 (+1.00%)
Is the Options Market Predicting a Spike in Kala Pharmaceuticals (KALA) Stock?

Investors need to pay close attention to Kala Pharmaceuticals (KALA) stock based on the movements in the options market lately.

KALA : 4.05 (+1.00%)
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2017 Equity Incentive...

KALA : 4.05 (+1.00%)
Research Report Identifies Dean Foods, Kala Pharmaceuticals, Buckeye Partners, Rockwell Medical, United Fire Group, and Clearwater Paper with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Dean Foods Company (NYSE:DF),...

DF : 1.19 (+12.26%)
RMTI : 2.38 (-1.65%)
UFCS : 45.73 (-0.35%)
KALA : 4.05 (+1.00%)
BPL : 41.05 (-0.12%)
CLW : 16.25 (-0.31%)
Kala Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY(TM) mucus-penetrating...

KALA : 4.05 (+1.00%)
Implied Volatility Surging for Kala Pharmaceuticals (KALA) Stock Options

Kala Pharmaceuticals (KALA) needs investors to pay close attention to the stock based on moves in the options market lately.

KALA : 4.05 (+1.00%)
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

--August 15, 2019 Prescription Drug User Fee Act (PDUFA) target action date for KPI-121 0.25% for the temporary relief of signs and symptoms of dry eye disease

KALA : 4.05 (+1.00%)
Kala Pharmaceuticals to Present at Upcoming Investor Conferences in March

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY(TM) mucus-penetrating...

KALA : 4.05 (+1.00%)
Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY(TM) mucus-penetrating...

KALA : 4.05 (+1.00%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
AIZ +0.09 , WELL -0.03 , SBAC +0.11 , CCI +0.94 , SO +0.50
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar